MedTrace Logo

Study of ONO-1101 in Patients Scheduled for Coronary Angiography

NCT00560209 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2012-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

Conditions

Interventions

DRUG

ONO-1101

placebo for 1 minute IV

DRUG

ONO-1101

0.06 mg/kg for 1 minute IV

DRUG

ONO-1101

0.125 mg/kg for 1 minute IV

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Shinichi Kikawa · Ono Pharmaceutial Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-11-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560209 on ClinicalTrials.gov